PLPL: A Potential Drug Target for Tissue Health and Disease (G56936)

Target Name: CCDC177

NCBI ID: G56936

CCDC177

PLPL: A Potential Drug Target for Tissue Health and Disease

CCDC177 (Plasma-derived long terminal repeat fragment), also known as PLPL, is a protein that is expressed in various tissues of the human body, including the liver, lung, and brain. It is a member of the plasmin system, which is a group of enzymes that help to remove damaged or dysfunctional cells from the body.

PLPL is of particular interest as a potential drug target because of its involvement in a number of diseases, including thrombosis, cancer, and neurodegenerative disorders. It is also associated with a number of adverse events, including bleeding and decreased platelet count, which can make it a useful biomarker for drug development.

One of the key functions of PLPL is its role in the plasmin system. Plasmin is a protein that helps to break down damaged or dysfunctional cells, and it is activated when a cell is damaged or has been exposed to an invasive agent. When PLPL is activated, it helps to remove the damaged or dysfunctional cell from the body, which can be important for maintaining tissue health and preventing the development of diseases.

In addition to its role in the plasmin system, PLPL is also involved in a number of other processes in the body. For example, it is involved in the regulation of inflammation, and it has been shown to have anti-inflammatory effects. It is also involved in the regulation of blood pressure, and has been shown to have a positive effect on blood pressure in individuals with hypertension.

PLPL is also of interest as a potential drug target because of its association with a number of diseases. Thrombosis is a condition in which a blood clot forms in the body and can cause serious complications, including stroke, heart attack, and death. PLPL is involved in the regulation of blood clot formation, and it is possible that drugs that target PLPL may be effective in treating thrombosis.

In addition to its association with thrombosis, PLPL is also associated with a number of other diseases, including cancer and neurodegenerative disorders. For example, PLPL has been shown to be involved in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. It is also involved in the regulation of the immune system, and has been shown to have a positive effect on immune function.

PLPL is also of interest as a potential biomarker for drug development because of its association with a number of adverse events, including bleeding and decreased platelet count. These adverse events can make it difficult for patients to receive effective treatment, and targeting PLPL with drugs that do not cause these adverse effects may be an important step in the development of new treatments.

In conclusion, PLPL is a protein that is expressed in various tissues of the human body that is involved in a number of important processes in the body, including the regulation of the plasmin system, inflammation, blood pressure, and immune function. It is of particular interest as a potential drug target because of its involvement in a number of diseases, including thrombosis, cancer, and neurodegenerative disorders. It is also associated with a number of adverse events, including bleeding and decreased platelet count, which can make it difficult for patients to receive effective treatment. Further research is needed to fully understand the role of PLPL in the body and its potential as a drug target.

Protein Name: Coiled-coil Domain Containing 177

The "CCDC177 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC177 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets